Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete resolution of acute GVHD
within 90 days from start of therapy
No
Moshe Yeshurun, MD
Principal Investigator
Davidoff cancer center, Beilinson hospital, Rabin Medical Center
Israel: Ethics Commission
0388-11-RMC
NCT01596075
July 2012
Name | Location |
---|